Radetec’s technology utilises a world-first technique, which optimises the performance of QDs with conventional lateral flow assay (LFA) to produce a vastly more sensitive (10-100 times increase in sensitivity), faster (results within 10mins) and inexpensive (reduce existing costs by upwards of 50%) test kits for the diagnosis of various STIs.
The critical part of LFA is the conjugation chemistry between a label and a disease-specific antibody, which provides the source of sensitivity. The existing and most widely used label is colloidal gold, however a high concentration of gold-antibody conjugates is required for effective testing. As a consequence, colloidal gold-based tests present two main disadvantages: a) large amounts of antibodies are required, which translate to higher cost to produce the test kits; b) it cannot detect early stage viral infections due to low pathogen load, which translate into poor clinical sensitivity.
QDs-based tests effectively address these two limitations. QDs generate very bright fluorescence (brighter than other fluorescence molecules), meaning that a lower amount of QD-antibody is necessary to generate a signal. This high brightness also allows the detection of lower concentration of pathogens, enabling early diagnosis and treatment, with substantial healthcare cost savings.
The conjugation between QDs and antibodies presents the biggest hurdle of their application with LFA. A major challenge is that every antibody is different, therefore it is necessary to establish different reaction conditions for each antibody, resulting in high costs for the development of a test.